In vivo electrophysiology of nigral and thalamic neurons in alpha-synuclein-overexpressing mice highlights differences from toxin-based models of parkinsonism.
Numerous studies have suggested that alpha-synuclein plays a prominent role in both familial and idiopathic Parkinson's disease (PD). Mice in which human alpha-synuclein is overexpressed (ASO) display progressive motor deficits and many nonmotor features of PD. However, it is unclear what in vivo pathophysiological mechanisms drive these motor deficits. It is also unknown whether previously proposed pathophysiological features (i.e., increased beta oscillations, bursting, and synchronization) described in toxin-based, nigrostriatal dopamine-depletion models are also present in ASO mice. To address these issues, we first confirmed that 5- to 6-mo-old ASO mice have robust motor dysfunction, despite the absence of significant nigrostriatal dopamine degeneration. In the same animals, we then recorded simultaneous single units and local field potentials (LFPs) in the substantia nigra pars reticulata (SNpr), the main basal ganglia output nucleus, and one of its main thalamic targets, the ventromedial nucleus, as well as LFPs in the primary motor cortex in anesthetized ASO mice and their age-matched, wild-type littermates. Neural activity was examined during slow wave activity and desynchronized cortical states, as previously described in 6-hydroxydopamine-lesioned rats. In contrast to toxin-based models, we found a small decrease, rather than an increase, in beta oscillations in the desynchronized state. Similarly, synchronized burst firing of nigral neurons observed in toxin-based models was not observed in ASO mice. Instead, we found more subtle changes in pauses of SNpr firing compared with wild-type control mice. Our results suggest that the pathophysiology underlying motor dysfunction in ASO mice is distinctly different from striatal dopamine-depletion models of parkinsonism.
Department of Biology, Emory University, Atlanta, Georgia;
C J
CJ
Lobb
A K
AK
Zaheer
Y
Y
Smith
D
D
Jaeger
D000200:Action Potentials; D000818:Animals; D001611:Beta Rhythm; D006801:Humans; D008297:Male; D051379:Mice; D009044:Motor Cortex / Q000503:physiopathology; D009474:Neurons / Q000378:metabolism / Q000502:physiology*; D016627:Oxidopamine / Q000633:toxicity; D010300:Parkinson Disease / Q000235:genetics / Q000503:physiopathology*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000503:physiopathology*; D013378:Substantia Nigra / Q000166:cytology / Q000378:metabolism / Q000503:physiopathology*; D013788:Thalamus / Q000166:cytology / Q000378:metabolism / Q000503:physiopathology*; D051844:alpha-Synuclein / Q000235:genetics* / Q000378:metabolism
C497604:SNCA protein, human; D051844:alpha-Synuclein; D016627:Oxidopamine
Parkinson's disease; basal ganglia; mouse; recording; thalamus